Diffuse Large B-cell Lymphoma research hub
34 indexed studies · 14 currently recruiting
- active not recruitingPHASE2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This study is testing a new medicine, Selinexor, for people in the UK with a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded to previous treatments. It aims to see if Selinexor can help when other options haven't worked.
United States · Australia · Austria - active not recruitingPHASE3
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
This study is looking into a new drug, epcoritamab, for people with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It compares epcoritamab combined with standard treatment (R-CHOP) to R-CHOP alone, to see if the new combination works better.
United States · Australia · Austria - active not recruitingPHASE1, PHASE2
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
This study is testing a new medicine called epcoritamab, sometimes with other treatments, for people with B-cell non-Hodgkin lymphoma. Doctors want to check if it's safe and if it helps shrink the cancer. It's given by injection under the skin.
United States · Australia · Belgium - active not recruitingPHASE3
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
This study looks at a new combination of two drugs, tafasitamab and lenalidomide, for adults in the UK with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It's for those whose cancer has returned or hasn't responded well to previous treatments and who can't have a stem cell transplant.
Bulgaria · Croatia · Czechia - active not recruitingPHASE3
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
This study is for people in the UK with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has returned or not responded to previous treatments. It aims to see if adding an experimental drug, brentuximab vedotin, to two existing treatments (rituximab and lenalidomide) works better than the two existing treatments alone.
United States · Australia · Belgium - active not recruitingPHASE3
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
This study compares a new medicine called epcoritamab with standard chemotherapy for a type of lymphoma (DLBCL) that hasn't responded to earlier treatments. It aims to see if epcoritamab is safer and more effective for patients who can't have or have already had a stem cell transplant.
United States · Australia · Austria - recruitingPHASE1, PHASE2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
This study is testing a new drug, Zilovertamab Vedotin, for children and young adults aged 6 months to 25 years with certain blood cancers (like some types of leukaemia and lymphoma) and solid tumours (like neuroblastoma and Ewing sarcoma) that have come back or not responded to previous treatments.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
This study is testing a new medicine, Tulmimetostat, for people with advanced cancers like solid tumours and lymphomas. It's looking at how safe it is, any side effects, and if it helps to shrink tumours.
United States · France · Italy - recruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
This study is testing a new medicine called BGB-16673 for people with certain types of B-cell cancers, like lymphoma or chronic leukaemia. It aims to find the right dose and see how well it works and if it's safe. It's an early-stage trial.
United States · Australia · Brazil - active not recruitingPHASE3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study looks at new treatments for Diffuse Large B-Cell Lymphoma (DLBCL) that has come back or not responded to previous treatment. It compares a new drug called epcoritamab with standard treatments to see which works best and is safest.
United States · Argentina · Australia - recruiting
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
This study aims to understand cancer better by collecting lots of information from cancer samples. Researchers will look at patient health details, detailed pictures of cancer tissue, and genetic information to find new ways to treat cancers like Diffuse Large B Cell Lymphoma and other solid tumours.
United States · France · Germany - active not recruitingNA
RadiothErapy priMIng for CAR-T
This study is for people with a type of blood cancer called Diffuse Large B Cell Lymphoma, whose condition has come back or not responded to previous treatments. It looks at giving a small amount of radiotherapy before a special treatment called CAR-T to see if it makes the CAR-T treatment work better.
United Kingdom - recruitingPHASE3
Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line
This study looks at whether a special exercise programme, called Adapted Physical Activity, can help people aged 65 and over with a common type of lymphoma called diffuse large B-cell lymphoma (DLBCL). We want to see if it improves how long patients live without their cancer coming back.
France - active not recruitingPHASE2
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
This study looks at a new combination of treatments for a type of lymphoma called diffuse large B-cell lymphoma. It combines standard chemotherapy with a newer drug called pembrolizumab to see if it works better for people whose lymphoma has come back or hasn't responded to previous treatment.
United Kingdom - active not recruitingPHASE1, PHASE2
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
This study is testing a new cell therapy called rapcabtagene autoleucel for different types of blood cancers, including certain lymphomas and leukaemias. It aims to see if the treatment is safe, works well, and how best to give it, sometimes with another drug called ibrutinib.
United States · Australia · Austria - active not recruitingPHASE3
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
This study is looking at a new treatment combination for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It combines a new drug, tafasitamab, and another drug, lenalidomide, with standard chemotherapy to see if it works better than chemotherapy alone.
United States · Argentina · Australia - recruitingPHASE1
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
This study is testing a new medicine, IKS03, for people with certain types of advanced B-cell non-Hodgkin lymphoma. It aims to find the safest dose and see how well it works. This is an early-stage study, meaning it's the first time it’s being given to people.
United States · Australia · Canada - active not recruitingPHASE3
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
This study looks at a new drug called acalabrutinib combined with standard chemotherapy (R-CHOP) for a type of blood cancer called Diffuse Large B-Cell Lymphoma, in people who haven't had treatment before. We want to see if this combination works better and is safe.
United States · Australia · Austria - recruitingPHASE1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
This study is testing a new drug, ABBV-319, for people with certain types of blood cancer like lymphoma or leukemia that have come back or are not responding to current treatments. Researchers want to see if it's safe, how it moves through the body, and if it helps fight the cancer.
United States · Australia · Canada - recruitingPHASE3
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
This study looks at adding a new drug, acalabrutinib, to standard treatment (R-miniCHOP) for older adults with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It wants to see if this addition can help people live longer without their cancer getting worse.
Germany - recruitingPHASE3
Study of Out of Specification for Tisagenlecleucel
This study looks at a special cell therapy called tisagenlecleucel for difficult-to-treat blood cancers in children and adults. We're checking if the treatment is safe and works well, even when the cell product doesn't quite meet all the usual manufacturing checks.
Canada · Japan - active not recruitingPHASE3
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug, glofitamab, combined with standard chemotherapy (GemOx) for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatments. It compares this new combination to a standard treatment.
United States · Australia · Belgium - recruitingPHASE3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
This study looks at a new drug, zilovertamab vedotin, combined with standard treatment for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). Researchers want to see if this new combination helps people live longer without their cancer growing or spreading, compared to standard treatment alone.
United States · Argentina · Australia - active not recruitingNA
Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells
This study looks at a faster way to check for leftover lymphoma cells after CAR-T cell treatment. By testing blood for tiny bits of cancer DNA, doctors hope to catch the disease coming back sooner and offer earlier extra treatment to improve patient outcomes.
France - recruitingPHASE3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
This study offers ongoing access to a drug called ibrutinib for people already using it for certain blood cancers and conditions, who are still benefiting. It also helps gather more long-term information on how safe and effective ibrutinib is.
United States · Argentina · Australia - active not recruitingPHASE1
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
This study is looking into a new tablet medicine, ABBV-525, for adults with certain B-cell cancers like lymphoma and leukaemia. It aims to check its safety, how well the body handles it, and if it could help treat these conditions.
United States · Australia · Belgium - active not recruitingPHASE2
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
This study is testing if adding a new drug, acalabrutinib, to standard chemotherapy (R-CHOP) helps people with a type of lymphoma called Diffuse Large B-cell Lymphoma (DLBCL) who haven't had treatment before. Researchers want to see if this new combination works better.
United Kingdom - active not recruitingPHASE2
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
This study looks at new treatments for a type of blood cancer called Diffuse Large B-Cell Lymphoma in older patients who can't have standard chemotherapy. It tests a drug called epcoritamab, with or without another drug called lenalidomide, to see how well they work and if they are safe.
United States · Austria · Belgium - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
This study is testing a new combination treatment for an aggressive type of cancer called Diffuse Large B-cell Lymphoma. It's for people who haven't had treatment before and might be too frail for standard options. Researchers want to see if the new treatment is safe and effective.
Italy · Spain - recruitingPHASE1, PHASE2
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
This study is testing two medicines, KRT-232 and acalabrutinib, together for people with certain types of lymphoma or leukaemia that have come back or not responded to previous treatments. Researchers want to see if this combination is safe and works well.
United States · Australia · Belgium - ongoing, recruitingPhase I and Phase II (Integrated)- Other
Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell Lymphoma who are treated with CD19-directed CAR T-cell therapy: a pilot study
This study looks at a special scan before CAR T-cell therapy for lymphoma. It uses a tracer to see how certain proteins in lymphoma cells react. The aim is to understand how this scan can predict treatment success and help tell the difference between active lymphoma and normal swelling.
Netherlands - recruiting
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
This study looks at how a new drug called epcoritamab works for adults with Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) in real-life settings. It aims to see how well it treats these blood cancers when given as part of regular care.
Argentina · Australia · Austria - active not recruitingPHASE2
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
This study looks at a new drug, Iopofosine I-131, for people with certain B-cell cancers like Waldenstrom, myeloma, or lymphoma, who haven't responded well to other treatments. It aims to see how safe and effective this new approach is.
United States · Australia · Brazil